<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395705</url>
  </required_header>
  <id_info>
    <org_study_id>Henan CH</org_study_id>
    <nct_id>NCT02395705</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of neo-adjuvant chemotherapy on survival of patients with thoracic esophageal&#xD;
      squamous cell carcinomas remains the most controversial part of neo-adjuvant therapy for&#xD;
      esophageal carcinomas. One of our objectives is to evaluate whether the neo-adjuvant therapy&#xD;
      with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total&#xD;
      2-field lymph node dissection improves the overall survival of thoracic esophageal cancer&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of Neo-adjuvant chemotherapy on survival of patients with thoracic esophageal&#xD;
      squamous cell carcinomas remains the most controversial part of Neo-adjuvant therapy for&#xD;
      esophageal carcinomas. Therefore, the optimal management of resectable esophageal squamous&#xD;
      cell carcinomas differs widely among different areas based on local randomized controlled&#xD;
      trials.&#xD;
&#xD;
      The neo-adjuvant chemotherapy might be a good strategy if sufficient local control is&#xD;
      achieved by surgical treatment. This study defined the detail of surgery procedure and the&#xD;
      region of lymphadenectomy and adopted cisplatin and paclitaxel as neoadjuvant chemotherapy&#xD;
      regimens. We try to evaluate the efficacy and safety of this neo-adjuvant strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Removal rate (R0 resection rate)</measure>
    <time_frame>perioperative period</time_frame>
    <description>The R0 resection rate of two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Rate of Operative Complication</measure>
    <time_frame>perioperative period</time_frame>
    <description>Complication rate after operation before discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Mortality of perioperation</measure>
    <time_frame>perioperative period</time_frame>
    <description>Mortality of perioperation 20 days before operation and 30 days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Days of Hospitalization</measure>
    <time_frame>perioperative period</time_frame>
    <description>Days of Hospitalization after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Thoracic Drainage</measure>
    <time_frame>perioperative period</time_frame>
    <description>Thoracic Drainage days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Quantity of bleeding</measure>
    <time_frame>perioperative period</time_frame>
    <description>blood lose during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Time of operation</measure>
    <time_frame>perioperative period</time_frame>
    <description>the time from open thoracic cavity to the closure of the thoracic cavity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 years</time_frame>
    <description>ECOG, KPS, NRS-2002, EORTC QLQ-ST018, EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of neo-adjuvant chemotherapy--response rate</measure>
    <time_frame>1-4 days before operation</time_frame>
    <description>Criteria:Response Evaluation Criteria in Solid Tumorsï¼ŒRECIST. Pathologic Complete Response Rate. Pathologic Response Rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicities of neo-adjuvant chemotherapy</measure>
    <time_frame>from chemotherapy to perioperative period</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Event,Version 3.0(CTC AE3.0). The complete rate of protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic factors</measure>
    <time_frame>5 years</time_frame>
    <description>prognostic factors for overall survival of both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive factors</measure>
    <time_frame>2 years</time_frame>
    <description>predictive factors for the efficiency of neo-adjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">528</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Neo-adjuvant chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neo-adjuvant chemotherapy(cisplatin and paclitaxel):&#xD;
Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.&#xD;
Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.&#xD;
Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.&#xD;
Surgery:&#xD;
2-3weeks after Neo-adjuvant chemotherapy&#xD;
Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.&#xD;
Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery alone group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgery:&#xD;
2-3weeks after Neo-adjuvant chemotherapy&#xD;
Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.&#xD;
Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and paclitaxel</intervention_name>
    <description>Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.&#xD;
Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.&#xD;
Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.</description>
    <arm_group_label>Neo-adjuvant chemotherapy group</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage IIA to&#xD;
             IIIB, (7th Union for International Cancer Control, UICC-TNM).&#xD;
&#xD;
          2. Patients must not have received any prior anticancer therapy of esophageal carcinoma.&#xD;
&#xD;
          3. Age ranges from 18 to 75 years.&#xD;
&#xD;
          4. Without operative contraindication.&#xD;
&#xD;
          5. Absolute white blood cells count â‰¥4.0Ã—109/L, neutrophil â‰¥1.5Ã—109/L, platelets&#xD;
             â‰¥100.0Ã—109/L, hemoglobin â‰¥90g/L, and normal functions of liver and kidney, total&#xD;
             bilirubinï¼ˆTBILï¼‰â‰¤1.5N, aspartate aminotransferase (AST)â‰¤2.5N, alanine&#xD;
             aminotransferase(ALT)â‰¤2.5N, prothrombin time(PT)â‰¤1.5N, and activated partial&#xD;
             thromboplastin time(APTT) is in normal range, endogenous creatinine clearance&#xD;
             rate(CRE)â‰¤1.5N.&#xD;
&#xD;
          6. Patients must not have diagnosed with other cancer and must not received any prior&#xD;
             anticancer therapy except prostatic cancer with more than 5 years disease-free&#xD;
             survival(DFS).&#xD;
&#xD;
          7. expected R0 resection.&#xD;
&#xD;
          8. ECOG 0ï½ž2.&#xD;
&#xD;
          9. Signed informed consent document on file. 10.No metastatic lymph node in cervical by&#xD;
             color doppler sonography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multiple primary cancer.&#xD;
&#xD;
          2. The subject cannot understand and sign the informed consent form(ICF).&#xD;
&#xD;
          3. Patients with concomitant hemorrhagic disease.&#xD;
&#xD;
          4. Any un expected reason for patients can't get operation.&#xD;
&#xD;
          5. Inability to use gastric conduit after esophagectomy because of a prior surgery.&#xD;
&#xD;
          6. Pregnant or breast feeding.&#xD;
&#xD;
          7. Patients are diagnosed or suspected to be allergic to cisplatin or Paclitaxel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin Li, MD.&amp;PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>FuZhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Uniersity Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anyang cancer hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Province Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan Universitay Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Yin Li</investigator_full_name>
    <investigator_title>Vice-President, Director of thoracic surgery department, Henan Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

